Aviva
RIGL icon

Aviva’s Rigel Pharmaceuticals RIGL Stock Holding History

Aviva’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$410K Buy
15,172
+3,971
+35% +$133K ﹤0.01% 786
2025
Q4 		$480K Sell
11,201
-2,487
-18% -$93.8K ﹤0.01% 794
2025
Q3 		$388K Sell
13,688
-10,101
-42% -$302K ﹤0.01% 850
2025
Q2 		$446K Buy
23,789
+3,285
+16% +$62.3K ﹤0.01% 828
2025
Q1 		$369K Buy
+20,504
New +$416K ﹤0.01% 830

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aviva's RIGL Position: Q1 2026 in Review

Aviva increased its Rigel Pharmaceuticals (RIGL) stake by 35% in Q1 2026, buying an estimated $133K and bringing the position to 15,172 shares worth $410K. The position accounts for ﹤0.01% of the portfolio, ranked #786.

Aviva first reported a position in RIGL in Q1 2025 and has held it in 5 quarters since. The position peaked at $480K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Aviva held 15,172 shares of Rigel Pharmaceuticals worth $410K as of Q1 2026.
  • Aviva bought 3,971 Rigel Pharmaceuticals shares in Q1 2026, an estimated $133K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Aviva's portfolio in Q1 2026, its #786 holding.
  • Aviva first reported a position in Rigel Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Aviva's Rigel Pharmaceuticals position peaked at $480K in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Aviva's 13F filing for Q1 2026, filed 14 May 2026.